Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus

Tae Jung Oh, Chang Ho Ahn, Bo-Rahm Kim, Kyoung Min Kim, Jae Hoon Moon, Soo Lim, Kyong Soo Park, Cheong Lim, HakChul Jang, Sung Hee Choi, Tae Jung Oh, Chang Ho Ahn, Bo-Rahm Kim, Kyoung Min Kim, Jae Hoon Moon, Soo Lim, Kyong Soo Park, Cheong Lim, HakChul Jang, Sung Hee Choi

Abstract

Context: A previous genome-wide association study showed that a genetic variant of sortilin was associated with the risk of coronary artery disease (CAD). However, the role of circulating sortilin is still unknown. We investigated the potential role of plasma sortilin as a biomarker for CAD and diabetes mellitus.

Methods: We enrolled statin-naïve subjects with CAD (n = 31) who underwent coronary artery bypass surgery and control subjects (n = 116) who were free from CAD as evaluated by coronary CT angiography. The presence of diabetes mellitus was evaluated and plasma sortilin levels were measured with a commercial ELISA kit.

Results: Plasma sortilin levels were higher in subjects with CAD and subjects with diabetes mellitus than in those without CAD or diabetes mellitus. Subjects in the highest sortilin tertile group were older and had higher glucose and HbA1c levels, but lipid profiles in the three tertile groups were comparable. Multivariable logistic regression analysis revealed that sortilin levels were independently associated with CAD. In addition, the receiver operating characteristic curve analysis showed that plasma sortilin levels could identify the presence of CAD or diabetes mellitus.

Conclusions: Elevated circulating sortilin levels are associated with CAD and diabetes mellitus and can be used as a biomarker of both diseases in statin-naïve subjects.

Keywords: Biomarker; Coronary artery disease; Diabetes mellitus; Proneurotensin; Sortilin.

Figures

Fig. 1
Fig. 1
Circulating sortilin levels depending on the existence of coronary artery disease. Data are shown as mean ± SD. ***P < 0.001 using a nonparametric t test
Fig. 2
Fig. 2
ROC curve analysis of the ability of sortilin to predict the presence of coronary artery disease

References

    1. Sajankila N, Como JJ, Claridge JA. Upcoming rules and benchmarks concerning the monitoring of and the payment for surgical infections. Surg Clin North Am. 2014;94(6):1219–1231. doi: 10.1016/j.suc.2014.08.012.
    1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi: 10.1016/j.diabres.2009.10.007.
    1. Ortega Moreno L, Copetti M, Fontana A, De Bonis C, Salvemini L, Trischitta V, et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15:17. doi: 10.1186/s12933-016-0339-z.
    1. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–1523. doi: 10.1056/NEJMoa1310799.
    1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–1146. doi: 10.1161/01.CIR.100.10.1134.
    1. Adela R. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res. 2015
    1. Odegaard AO, Jacobs DR, Jr, Sanchez OA, Goff DC, Jr, Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016;15:51. doi: 10.1186/s12933-016-0369-6.
    1. von Scholten BJ, Reinhard H, Hansen TW, Lindhardt M, Petersen CL, Wiinberg N, et al. Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:59. doi: 10.1186/s12933-015-0225-0.
    1. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357(5):443–453. doi: 10.1056/NEJMoa072366.
    1. Kjolby M, Andersen OM, Breiderhoff T, Fjorback AW, Pedersen KM, Madsen P, et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010;12(3):213–223. doi: 10.1016/j.cmet.2010.08.006.
    1. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40(2):189–197. doi: 10.1038/ng.75.
    1. Hermey G. The Vps10p-domain receptor family. Cell Mol Life Sci. 2009;66(16):2677–2689. doi: 10.1007/s00018-009-0043-1.
    1. Navarro V, Vincent JP, Mazella J. Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line. Biochem Biophys Res Commun. 2002;298(5):760–764. doi: 10.1016/S0006-291X(02)02564-0.
    1. Ogawa K, Ueno T, Iwasaki T, Kujiraoka T, Ishihara M, Kunimoto S, et al. Soluble sortilin is released by activated platelets and its circulating levels are associated with cardiovascular risk factors. Atherosclerosis. 2016;249:110–115. doi: 10.1016/j.atherosclerosis.2016.03.041.
    1. Januzzi JL, Jr, Lyass A, Liu Y, Gaggin H, Trebnick A, Maisel AS, et al. Circulating proneurotensin concentrations and cardiovascular disease events in the community: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2016;36(8):1692–1697. doi: 10.1161/ATVBAHA.116.307847.
    1. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20(7):302–309. doi: 10.1016/S0165-6147(99)01357-7.
    1. Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012;308(14):1469–1475. doi: 10.1001/jama.2012.12998.
    1. Li J, Song J, Zaytseva YY, Liu Y, Rychahou P, Jiang K, et al. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature. 2016;533(7603):411–415. doi: 10.1038/nature17662.
    1. Morris NJ, Ross SA, Lane WS, Moestrup SK, Petersen CM, Keller SR, et al. Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes. J Biochem. 1998;273(6):3582–3587.
    1. Nozue T, Hattori H, Ogawa K, Kujiraoka T, Iwasaki T, Michishita I. Effects of statin therapy on plasma proprotein convertase subtilisin/kexin type 9 and sortilin levels in statin-naive patients with coronary artery disease. J Atheroscler Thromb. 2016;23(7):848–856. doi: 10.5551/jat.33407.
    1. Leber AW, Knez A, Becker A, Becker C, von Ziegler F, Nikolaou K, et al. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: a comparative study with intracoronary ultrasound. J Am Coll Cardiol. 2004;43(7):1241–1247. doi: 10.1016/j.jacc.2003.10.059.
    1. Kim YK, Hwang MY, Kim YJ, Moon S, Han S, Kim BJ. Evaluation of pleiotropic effects among common genetic loci identified for cardio-metabolic traits in a Korean population. Cardiovasc Diabetol. 2016;15:20. doi: 10.1186/s12933-016-0337-1.
    1. Beaney KE, Cooper JA, McLachlan S, Wannamethee SG, Jefferis BJ, Whincup P, et al. Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids. Cardiovasc Diabetol. 2016;15(1):115. doi: 10.1186/s12933-016-0435-0.
    1. Strong A, Patel K, Rader DJ. Sortilin and lipoprotein metabolism: making sense out of complexity. Curr Opin Lipidol. 2014;25(5):350–357. doi: 10.1097/MOL.0000000000000110.
    1. Zhong LY, Cayabyab FS, Tang CK, Zheng XL, Peng TH, Lv YC. Sortilin: a novel regulator in lipid metabolism and atherogenesis. Clinica Chimica Acta. 2016;460:11–17. doi: 10.1016/j.cca.2016.06.013.
    1. Goettsch C, Hutcheson JD, Aikawa M, Iwata H, Pham T, Nykjaer A, et al. Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J Clin Investig. 2016;126(4):1323–1336. doi: 10.1172/JCI80851.
    1. Patel KM, Strong A, Tohyama J, Jin X, Morales CR, Billheimer J, et al. Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis. Circ Res. 2015;116(5):789–796. doi: 10.1161/CIRCRESAHA.116.305811.
    1. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466(7307):714–719. doi: 10.1038/nature09266.
    1. Strong A, Ding Q, Edmondson AC, Millar JS, Sachs KV, Li X, et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Investig. 2012;122(8):2807–2816. doi: 10.1172/JCI63563.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa